Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY22 results · Oct–Dec 2021
Marksans Pharma reported revenue from operations of ₹362.63 crore (up 1.2% from Q3 FY21) and net profit of ₹48.27 crore (down 18.1% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 362.63 | 358.36 | +1.2% | 361.20 | +0.4% |
| Other income | 12.06 | (3.17) | Turned profit | 8.57 | +40.7% |
| Total income | 374.69 | 355.19 | +5.5% | 369.77 | +1.3% |
| Profit before tax | 60.35 | 77.64 | −22.3% | 59.78 | +1.0% |
| Net profit for the period | 48.27 | 58.94 | −18.1% | 46.29 | +4.3% |
| EPS, basic (₹) | 1.20 | 1.42 | −15.5% | 1.11 | +8.1% |
| Net margin (%) | 13.3 | 16.4 | 12.8 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 165.94 | 168.46 | −1.5% | 168.85 | −1.7% |
| Other income | 12.06 | 6.24 | +93.3% | 8.60 | +40.3% |
| Total income | 178.00 | 174.70 | +1.9% | 177.45 | +0.3% |
| Profit before tax | 34.68 | 35.99 | −3.6% | 37.02 | −6.3% |
| Net profit for the period | 26.06 | 29.10 | −10.5% | 27.60 | −5.6% |
| EPS, basic (₹) | 0.64 | 0.71 | −9.9% | 0.67 | −4.5% |
| Net margin (%) | 15.7 | 17.3 | 16.3 |
Consolidated
- Filed with BSE
- 11 Feb 2022, 17:12 IST
- Board meeting
- 11 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2022, 17:12 IST
- Board meeting
- 11 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE